Dechra Veterinary Products has announced the launch of two new antibiotics to treat a range of bacterial infections in cats and dogs.

Doxybactin, a second generation Tetracycline, can be used to target conditions caused by bacteria sensitive to doxycycline such as rhinitis, bronchopneumonia, and interstitial nephritis in dogs and respiratory infections in cats. It will be available in multiple tablet strengths of 50 mg, 200 mg and 400 mg.

Spizobactin (spiramycin and metronidazole) is indicated for the treatment of (peri)oral and periodontal multi-bacterial infections in dogs such as those associated with gingivitis, stomatitis, glossitis, periodontitis, tonsillitis, dental fistula and other fistulous wounds in the oral cavity. It will be available in three different tablet strengths.

Both treatments are meat flavoured and the tablets can be divided twice for accurate dosing. This, Dechra says, is to help avoid the development of antibiotic resistance associated with under dosing.

Dechra Brand Manager Carol Morgan said: "The launch of Spizobactin and Doxybactin to the UK and ROI markets will offer vets even more choice when it comes to the targeted and responsible use of antibiotics for these specific conditions.